Skip to main content
CT

Corcept Therapeutics

Corcept Therapeutics is a commercial-stage pharmaceutical company in Redwood City developing cortisol modulators for serious diseases, with Korlym approved for Cushing's syndrome and 30+ clinical studies.

Corcept Therapeutics is a commercial-stage pharmaceutical company based in Redwood City, California, that discovers and develops cortisol modulators acting at the glucocorticoid receptor to treat serious diseases. The company's work spans endocrinology, oncology, metabolism and neurology, combining small molecule drug discovery with clinical trial research. Its operations run from proprietary compound libraries and intellectual property development through to marketed products and late-stage studies.

The company's flagship product, Korlym (mifepristone), was approved by the FDA in 2012 as the first medication for patients with hypercortisolism, or Cushing's syndrome. Alongside it, Corcept is advancing a pipeline of proprietary cortisol modulators, with more than 30 ongoing clinical studies. Over more than 25 years of focused research, the company has discovered over 1,000 proprietary cortisol modulators, building an intellectual property estate in the field.

Corcept describes itself as science-first and led by scientists and collaborators, with a long-term orientation toward a singular mission in cortisol modulation. Roles at the company draw on backgrounds in pharmacology, endocrinology, clinical research, drug discovery and related disciplines; it operates from its Redwood City headquarters.

1 Open job

We use cookies

We use cookies to understand how this board is used and to improve it. Analytics run only if you accept. Cookie Policy